🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

62 results for “Vita” Clear

  1. Albendazole (400 mg) and/or Vitamin a

    United Therapeutics Europe Ltd

    Malnutrition

    phase 3 small molecule completed

    1 trial

  2. CardiolRx™ Placebo is a non-aqueous solution of medium chain triglycerides with 1.0% vitamin E as anti-oxidant. CardiolRx™ Placebo is a pale yellow clear liquid. The CardiolRx™ Placebo product is essentially the same as the CardiolRx™ drug product with the exception that the placebo does not include the active drug substance, cannabidiol., CardiolRx

    Cardiol Therapeutics

    Recurrent Pericarditis

    phase 3 small molecule active

    1 trial

  3. Cholecalciferol (Vitamin D/Vigantol oil)

    United Therapeutics Europe Ltd

    Respiratory Tract Infections

    phase 3 other completed

    1 trial

  4. Low-dose complex B-vitamins

    China SXT Pharmaceuticals

    Hyperhomocysteinemia

    phase 3 other completed

    1 trial

  5. SODIO CLORURO 0,9% BAXTER Soluzione per infusione, KETAMINA MOLTENI 50 mg/ml soluzione iniettabile

    Vita (Europe) Limited

    Major Depressive Disorder (MDD)

    phase 3 small molecule active

    1 trial

  6. SODIO CLORURO 0,9% BAXTER Soluzione per infusione, KETAMINA MOLTENI 50 mg/ml soluzione iniettabile

    Vita (Europe) Limited

    Major Depressive Disorder (MDD)

    phase 3 small molecule active

    1 trial

  7. Sildenafil placebo, Remidia, 20 mg, tabletki powlekane

    Cardiol Therapeutics

    Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.

    phase 3 small molecule active

    1 trial

  8. UVEDOSE 100 000 UI, solution buvable en ampoule

    Novo mesto

    Thyroidectomy is a common operation. Transient postoperative hypocalcemia is the main complication, resulting in clinical discomfort for patients, longer hospital stays and increased perioperative cost. Cholecalciferol is used to supplement vitamin D deficiency. We suppose that systematic pre-operative supplementation with cholecalciferol would allow a faster and more appropriate response to post-operative hypocalcemia

    phase 3 small molecule active

    1 trial

  9. Vitamin A

    United Therapeutics Europe Ltd

    Sepsis

    phase 3 other completed

    1 trial

  10. vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU)

    United Therapeutics Europe Ltd

    Mortality Through Six Months of Age

    phase 3 other completed

    1 trial

  11. vitamin D

    Takeda Pharmaceuticals International AG

    COVID-19

    phase 3 other completed

    1 trial

  12. -

    Vita (Europe) Limited

    Primary or advanced breast cancer LumA or ER+ Lobular subtypes.

    phase 2 small molecule active

    1 trial

  13. CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMETREXED, LIBTAYO 350 mg concentrate for solution for infusion.

    Vita (Europe) Limited

    non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  14. Cabazitaxel Accord 20 mg/ml concentrate for solution for infusion, Lutathera 370 MBq/mL solution for infusion, Xofigo 1100 kBq/mL solution for injection, Lynparza 150 mg film-coated tablets, Docetaxel Aurovitas 20 mg/ml concentrado para solución para perfusión, BAY 1841788

    Cancer Prevention Pharma (Ireland) Limited

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  15. Lamivudina Aurovitas 300 mg comprimidos recubiertos con película EFG

    Meda AB

    Mild Cognitive impairment due to Alzheimer Disease

    phase 2 small molecule active

    1 trial

  16. Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, Carboplatino Aurovitas 10 mg/ml concentrado para solución para perfusión EFG, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Glenmark 10 mg/ml solución para perfusión, Carboplatino Hikma 10 mg/ml soluzione per infusione, OMTX705, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Carboplatino Teva 10 mg/ml Concentrado para solución para perfusión, Carboplatino Accord 10 mg/ml concentrado para

    Pharma Mar S.A.

    Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. RBD4059 injection, Trombyl 75 mg tabletter, The corresponding placebo consist of the 25 mM phosphate buffer solution with 2 µg of vitamin b2 added for colouring purposes only

    Pharma Mar S.A.

    Stable Coronary Artery Disease

    phase 2 small molecule active

    1 trial

  18. Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer

    Vita (Europe) Limited

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

  19. The corresponding placebo solution consists of the 25 nM phosphate buffer solution with 4 μg of vitamin B2 added for colouring purposes only., RBD1016, Vemlidy 25 mg film-coated tablets.

    Pharma Mar S.A.

    Chronic hepatitis D virus infection

    phase 2 small molecule active

    1 trial

  20. Vitamin A (retinyl palmitate)

    United Therapeutics Europe Ltd

    Vitamin A Deficiency

    phase 2 small molecule completed

    1 trial

  21. Vitamin D

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  22. Vitamin D3

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 other completed

    1 trial

  23. Vitamin E

    NORTHWEST BIOTHERAPEUTICS INC

    Nonalcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  24. vitamin C

    China SXT Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources